Tirasemtiv

Unknown / undisclosed

DiscontinuedTroponin complex (skeletal muscle fast fibers)No recent registered activity
Discontinuedsponsor decision

Evidence outlook · program status

Discontinued (2017-11), after a negative readout

Tirasemtiv (CK-2017357) was Cytokinetics' first-generation fast skeletal muscle troponin activator in ALS. Its FY2017 Form 10-K states the Phase 3 VITALITY-ALS trial missed primary and secondary endpoints and that development was suspended; the same filing names reldesemtiv as the next-generation successor. The filing's word is 'suspend', and no tirasemtiv study has been registered in the nine years since. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Other / comorbidity
NCT02936635 · Cytokinetics
2016-10-17 – 2018-10-26 · Amyotrophic Lateral Sclerosis (ALS)
What this study did
NCT02496767 · Cytokinetics
2015-09-03 – 2017-09-27 · Amyotrophic Lateral Sclerosis
What this study did
Phase 2 (6)
Other / comorbidity
NCT01709149 · Cytokinetics
2012-10 – 2014-03 · Amyotrophic Lateral Sclerosis
What this study did
NCT01268280 · Cytokinetics
2010-12 – 2012-10 · Myasthenia Gravis
What this study did
NCT01486849 · Cytokinetics
2011-11 – 2012-03 · Amyotrophic Lateral Sclerosis
What this study did
NCT01378676 · Cytokinetics
2011-06 – 2012-03 · Amyotrophic Lateral Sclerosis
What this study did
NCT01131013 · Cytokinetics
2010-05 – 2011-03 · Intermittent Claudication, Peripheral Artery Disease
What this study did
NCT01089010 · Cytokinetics
2010-03 – 2010-11 · Amyotrophic Lateral Sclerosis
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

No upcoming readouts on record for this asset.